Pfizer (NYSE:PFE) Stock Price Up 1.7% – Still a Buy?

01 Apr 2026, 21:32 by Kim Johansen · The Markets Daily

Pfizer Inc. (NYSE:PFE – Get Free Report) was up 1.7% during trading on Wednesday . The company traded as high as $28.64 and last traded at $28.5610. Approximately 41,944,887 shares were traded during mid-day trading, a decline of 9% from the average daily volume of 45,975,992 shares. The stock had previously closed at $28.08.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Technical momentum: PFE has traded above its 50- and 200-day simple moving averages for months and is up year-to-date, signaling sustained investor confidence and helping support the stock. PFE Stock Trades Above 200 & 50-Day SMA
Positive Sentiment: Large vaccine contract enforced: A Belgian court ordered Poland and Romania to accept about €1.9bn ($2.2bn) of Pfizer COVID vaccines — a material cash flow and revenue takeaway that reduces inventory risk and supports near-term vaccine sales. Belgian court orders Poland, Romania to buy €1.9bn of Pfizer vaccines
Positive Sentiment: Oncology/pipeline optimism: Recent coverage highlights oncology successes and pipeline bets as reasons investors are upbeat despite a flat 2026 outlook — supports expectations for non-vaccine growth. Pfizer Stock Edges Higher on Oncology Wins
Positive Sentiment: Real‑world Ibrance data: An update from Pfizer’s Swedish observational study on Ibrance (palbociclib) could bolster confidence in ongoing oncology sales and label/reimbursement discussions if results are favorable. Pfizer’s Swedish Ibrance Study
Neutral Sentiment: Reshaping ViiV ownership: GSK and Shionogi have restructured ViiV Healthcare stakes as Pfizer exits the joint HIV venture — a strategic refocus that reduces direct HIV exposure but may free capital for other priorities; impact depends on redeployment. GSK and Shionogi Reshape ViiV Ownership
Negative Sentiment: COVID booster trial pause: Pfizer and BioNTech halted recruitment in a large U.S. trial of an updated COVID shot for adults 50–64 because enrollment was too low — a sign of weakening demand for new boosters that could limit future vaccine revenue growth. Pfizer, BioNTech halt US COVID study after recruitment struggles Pfizer, BioNTech Hit Pause On COVID Shot Trial
Negative Sentiment: Site closure: Reports say Pfizer will close a South San Francisco research site — could indicate cost-cutting or pipeline consolidation; investors may view this as a sign of reprioritization that could reduce near-term R&D capacity. Pfizer to close South San Francisco research site

Analyst Ratings Changes

A number of research firms have issued reports on PFE. Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. Bank of America dropped their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. HSBC boosted their price target on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Royal Bank Of Canada began coverage on shares of Pfizer in a research note on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price objective for the company. Finally, UBS Group began coverage on shares of Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.19.

View Our Latest Stock Analysis on PFE

Pfizer Stock Up 1.7%

The stock has a 50 day moving average price of $26.94 and a 200 day moving average price of $25.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The company has a market capitalization of $162.41 billion, a P/E ratio of 21.00 and a beta of 0.47.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Hedge funds have recently modified their holdings of the stock. Horizon Financial Services LLC raised its stake in shares of Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the period. Godfrey Financial Associates Inc. bought a new position in shares of Pfizer during the 4th quarter worth $26,000. YANKCOM Partnership purchased a new stake in Pfizer in the 4th quarter worth about $28,000. HFM Investment Advisors LLC raised its stake in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Finally, Grey Fox Wealth Advisors LLC bought a new stake in Pfizer in the 3rd quarter valued at about $29,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.